New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:20 EDTRDHLRedHill Biopharma announces commencement of bioavailability study of RHB-103
RedHill Biopharma together with IntelGenx announced the commencement of a comparative bioavailability clinical study comparing RHB-103 to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application for RHB-103, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. Results of the bioavailability study are anticipated by June.
News For RDHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
07:02 EDTRDHLRedHill Biopharma announces completion of enrollment in Phase III RHB-105 study
Subscribe for More Information
April 16, 2015
07:17 EDTRDHLRedHill Biopharma awarded additional U.S. patent for RHB-105
RedHill Biopharma announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent No. 14/179,197 covering the RHB-105 formulation. RHB-105 is a proprietary fixed-dose combination therapy of two antibiotics and a proton pump inhibitor, or PPI, in an all-in-one oral capsule, targeting an indication of first line treatment of Helicobacter pylori, or H. pylori, infection. The new RHB-105 patent application is entitled "Pharmaceutical Compositions for the Treatment of Helicobacter Pylori". Once granted, the patent is expected to be valid until at least 2034.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use